EGFR and colorectal carcinoma: Nowadays, standard fluoropyrimidine- based treatment options for metastatic CRC are varied by combination with other cytotoxic agents (such as oxaliplatin or irinotecan), biological targeted agents (such as bevacizumab and aflibercept), or anti EGFR antibodies, these treatments benefit patients with CRC that are refractory to first-line chemotherapy as well as those who are chemotherapy-naive.